Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fazpilodemab in NASH (BANFF)
NCT04171765Phase 2Terminated
- Sponsor
- Genentech
- Start
- Sep 2020
- Primary completion
- Jan 2023
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of fazpilodemab in Nonalcoholic steatohepatitis (NASH) (4 arms), sponsored by Genentech. Primary endpoint: Proportion of Participants With NASH Resolution on Overall Histopathological Reading Without Worsening of Fibrosis at 52 weeks. Started Sep 2020; status: terminated.
02
Drugs
fazpilodemab
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT04171765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04171765.